title: Involvement of PGE2 and RANTES in Staphylococcus aureus-induced fever in rats.
abstract: This study investigated the involvement of prostaglandins and regulated on activation, normal T cell expressed and secreted (RANTES), in fever induced by live Staphylococcus aureus (no. 25923, American Type Culture Collection) injection in rats. S. aureus was injected intraperitoneally at 10(9), 10(10), and 2 × 10(10) colony-forming units (CFU)/cavity, and body temperature (T(b)) was measured by radiotelemetry. The lowest dose of S. aureus induced a modest transient increase in T(b), whereas the two higher doses promoted similar long-lasting and sustained T(b) increases. Thus, the 10(10) CFU/cavity dose was chosen for the remaining experiments. The T(b) increase induced by S. aureus was accompanied by significant decreases in tail skin temperature and increases in PGE(2) levels in the cerebrospinal fluid (CSF) and hypothalamus but not in the venous plasma. Celecoxib (selective cyclooxygenase-2 inhibitor, 2.5 mg/kg po) inhibited the fever and the increases in PGE(2) concentration in the CSF and hypothalamus induced by S. aureus. Dipyrone (120 mg/kg ip) reduced the fever from 2.5 to 4 h and the PGE(2) increase in the CSF but not in the hypothalamus. S. aureus increased RANTES in the peritoneal exudate but not in the CSF or hypothalamus. Met-RANTES (100 μg/kg iv), a chemokine (C-C motif) receptor (CCR)1/CCR5 antagonist, reduced the first 6 h of fever induced by S. aureus. This study suggests that peripheral (local) RANTES and central PGE(2) production are key events in the febrile response to live S. aureus injection. As dipyrone does not reduce PGE(2) synthesis in the hypothalamus, it is plausible that S. aureus induces fever, in part, via a dipyrone-sensitive PGE(2)-independent pathway.
authors.affiliation: Laboratory of Pharmacology, Faculty of Pharmaceutical Sciences of Ribeirão Preto, University of São Paulo, Ribeirão Preto, São Paulo, Brazil.
authors.forename: Juliano M
authors.initials: JM
authors.lastname: Martins
authors.forename: Daniela T
authors.initials: DT
authors.lastname: Longhi-Balbinot
authors.forename: Denis M
authors.initials: DM
authors.lastname: Soares
authors.forename: Maria José
authors.initials: MJ
authors.lastname: Figueiredo
authors.forename: David do C
authors.initials: Ddo C
authors.lastname: Malvar
authors.forename: Miriam C C
authors.initials: MC
authors.lastname: de Melo
authors.forename: Giles A
authors.initials: GA
authors.lastname: Rae
authors.forename: Glória E P
authors.initials: GE
authors.lastname: Souza
mesh_terms: D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000494:pharmacology; D001202:Ascitic Fluid / Q000378:metabolism; D000068579:Celecoxib; D018946:Chemokine CCL5 / Q000037:antagonists & inhibitors / Q000096:biosynthesis* / Q000134:cerebrospinal fluid / Q000494:pharmacology; D052246:Cyclooxygenase 2 Inhibitors / Q000494:pharmacology; D015232:Dinoprostone / Q000096:biosynthesis* / Q000134:cerebrospinal fluid; D004177:Dipyrone / Q000494:pharmacology; D005334:Fever / Q000188:drug therapy / Q000209:etiology* / Q000378:metabolism*; D007031:Hypothalamus / Q000378:metabolism; D008297:Male; D011720:Pyrazoles / Q000494:pharmacology; D051381:Rats; D017208:Rats, Wistar; D015398:Signal Transduction; D013203:Staphylococcal Infections / Q000150:complications* / Q000378:metabolism*; D013211:Staphylococcus aureus / Q000472:pathogenicity; D013449:Sulfonamides / Q000494:pharmacology
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D018946:Chemokine CCL5; D052246:Cyclooxygenase 2 Inhibitors; D011720:Pyrazoles; C108335:RANTES, Met-; D013449:Sulfonamides; D004177:Dipyrone; D000068579:Celecoxib; D015232:Dinoprostone